Pharmaceutical giant AstraZeneca has unveiled plans to invest $4.5 billion in two new manufacturing facilities in Virginia, marking its largest-ever investment. The project is expected to create approximately 600 direct jobs and an additional 3,000 indirect positions.
The company emphasized the significance of the initiative, with CEO Pascal Soriot stating, “This investment will create thousands of jobs and strengthen America’s national security and health sovereignty.” He highlighted Virginia’s collaborative approach, noting the state’s ability to “move at incredible speed to build a better future.”
Virginia Gov. Glenn Youngkin praised the deal, calling it a “game-changer for American drug manufacturing” and crediting state programs like the Virginia Business Ready Sites Program for facilitating the project. Rep. John McGuire (R-VA) also celebrated the investment, stating it would generate high-paying jobs focused on chronic disease care and prevention.
AstraZeneca plans to expand the site’s capabilities, including production of cancer medicines and weight-loss drugs, with an additional $500 million allocated beyond initial projections. The project will receive up to $191.3 million in state funding contingent on job creation targets.
Local officials and state leaders hailed the development as a major economic boost for Albemarle County, underscoring Virginia’s growing appeal as a hub for biotech and advanced manufacturing.
